Economy/Home · Economy

Samchundang Pharm and Alteogen Flat, Hanmi Pharm Strong... Polarization Deepens Among Biopharmaceutical Stocks

Biopharmaceutical-related stocks showed mixed movements during the session on the 16th, resulting in a clear trend of stock-by-stock differentiation. Amid conti

CBC News Desk
Staff Reporter
5 min read
Samchundang Pharm and Alteogen Flat, Hanmi Pharm Strong... Polarization Deepens Among Biopharmaceutical Stocks
CBC News

Biopharmaceutical-related stocks showed mixed movements during the session on the 16th, resulting in a clear trend of stock-by-stock differentiation. Amid continued expectations for global new drug development and the expansion of the biosimilars market, share prices are diverging based on individual companies' supply and demand dynamics and pipeline progress.

Trends of Three Major Stocks

As of the afternoon, Samchundang Pharm traded at 264,000 won, down 2,000 won (0.75%) from the previous trading day. It had risen to 279,000 won during the session but gave up its gains and turned weak. Alteogen showed a flat trend at 349,000 won. It rose to as high as 356,500 won during the session but moved sideways without a clear direction. Meanwhile, Hanmi Pharm displayed strength, trading at 427,750 won, up 7,250 won (1.72%). It rose to as high as 435,500 won during the session, maintaining a steady trend.

Mixed Gains and Losses Within the Sector

Advancing stocks included Dongkook Pharm (+2.79%), Daewoong Pharmaceutical (+2.50%), Boryung (+2.49%), and Hanall Biopharma (+2.34%), which supported investor sentiment. On the other hand, Lspectomics (-3.68%), Aprogen Biologics (-3.51%), and Bionex (-2.20%) declined, showing that downward pressure was also significant.

Market Outlook and Key Variables

The market analyzes that as the global biopharmaceutical market grows and new drug development competition continues, interest in the mid- to long-term growth potential of domestic pharmaceutical and biotech companies remains high. In particular, technology exports, biosimilars, and next-generation therapeutic development outcomes are cited as key variables that determine corporate value.

Securities firms advise that since biopharmaceutical stocks are a sector with high volatility driven by R&D results, clinical outcomes, and technology transfer agreements, it is necessary to closely track individual companies' competitiveness and pipeline progress. Going forward, major clinical results and overseas business expansion are expected to be key factors determining the stock price trends of related stocks.

[※ This article was written with the assistance of an artificial intelligence (AI) analysis tool, and the final content was provided after an editorial process. The content included in this article is for informational purposes only and does not constitute a buy or sell recommendation for any specific stock or financial product. Investment decisions and the resulting responsibilities rest entirely with the investor. Actual results may vary depending on market conditions.]

CBC News Desk
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.